Abstract: A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.

Abstract: Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.

Abstract: Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.

Abstract: A biologically active peptide selected from growth factors, peptide hormones, interferons and cytokines and analogues and derivatives thereof, and bearing at least one chelating group linked to an amino group of said peptide, the chelating group being capable of complexing a detectable element and such amino group having no significant binding affinity to target receptors, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of target tissues or for therapy.

Abstract: The present invention provides a sugar derivative of a biologically active peptide, which derivative has a prolonged duration of action when compared to the non-sugar modified peptide, and contains at least on one of the amino acid units a sugar residue which is attached to an amino group thereof by a coupling other than a direct N-glycosidic bond, and additionally, when it is a condensation product of a carboxyl group containing sugar and a peptide with less than 8 amino acid units, by a coupling other than a direct amide bond.

Abstract: Peptide derivatives selected from (i) a calcitonin peptide and a LHRH antagonist peptide modified by at least one sugar residue and/or at least one short polyhydroxy compound or derivative, and (ii) a calcitonin peptide modified by at least one formyl and/or at least C.sub.3-5 alkyl attached to an amino group other than a N-terminal amino group, and (iii) a calcitonin peptide modified by a combination of said substituents, with the provisos thati) when the calcitonin peptide comprises at least one sugar residue a), this sugar residue is attached by a coupling other than a direct N-glycosidic bond to an .omega.-amino group of an .omega.-amino substituted side chain in the 24 position, andii) when the LHRH antagonist comprises at least one sugar residue a), this sugar residue is an Amadori sugar residue attached by a coupling other than a direct N-glycosidic bond to an .omega.-amino group of an .omega.

Abstract: Somatostatin analogues and derivatives in free form or in pharmaceutically acceptable salt or complex form are useful for treating degenerative and inflammatory processes in bone or catilage, e.g. arthritic conditions or diseases.

Abstract: A compound of formula I ##STR1## wherein R is H or R'CO wherein R'CO is an acyl radical of a carboxylic acid,Y.sub.1 is the radical linked to an alpha carbon atom an .alpha.-amino acid,Y.sub.2 is the radical linked to an alpha carbon atom of an .alpha.-amino acid, ##STR2## --CH.sub.2 --S--S--CH.sub.2 --CH.sub.2 --COOH, --(CH.sub.2).sub.p --COOH or --CH.sub.2 --S--Y.sub.3,Y.sub.3 is (C.sub.1-4)alkyl or benzyl optionally substituted by methyl or methoxy,or CH.sub.3 CO--NH--CH.sub.2 --,n is 1 to 4,A.sub.6 is Thr or D-Thr,p is 3 to 5,A.sub.8 is the aminoacyl radical of a neutral, lipophilic L-.alpha.-aminoacid,A.sub.9 is the aminoacyl radical of a neutral, lipophilic L- or D-.alpha.-aminoacid,Z is a polypeptide radical corresponding to the polypeptide radical in positions 10 to 31 of a natural calcitonin or a derivative or analogue thereof having a hypocalcemic effect,wherein, when there is more than one Y.sub.1 radical, these are the same or different, and with the exception of radical A.sub.

Abstract: Somatostatine derivatives of the general formula ##STR1## wherein either (a)A is ##STR2## W is -CO-N(A.sub.4) or -N(A.sub.5)-CO- and Y.sub.1 and Y.sub.2 are H or together a bondor (b)A is H, alkyl, phenylalkyl or RCO andY.sub.1 and Y.sub.2 are acyl groups as defined in claim 1,A', B, C, D, E, F, A.sub.1, A.sub.2, A.sub.3, A.sub.4, A.sub.5, R and Z having the meanings recited in claim 1, have pharmacological, in particular GH-, gastric- and pancreatic secretion inhibiting activity.

Abstract: Straight-chain or mono-cyclicpolypeptides comprising a heptapeptide moiety, said moiety having in the 1-position (N-terminal) an .alpha.-N-phenylalkylated, optionally ring-substituted phenylalanine residue, in the 2-position a cysteine residue, in the 3-position an optionally ring-substituted phenylalanine residue, in the 4-position an optionally benzene-ring-substituted tryptophan residue, in the 5-position an optionally .epsilon.-N-alkylated lysine residue and in the 7-position (C-terminal) a cysteine or cysteinol residue the S-atoms of the cysteine residue at the 2-position and the cysteine or cysteinol residue at the 7-position being linked together in the case of the mono-cyclic polypeptides to form an -S-S-bridge, whereby the residues at the 1-, 2-, 4-, 6-, and 7-positions of said heptapeptide moiety may each be in the (L)- or (D)-configuration and the residues at the 4-, 5- and 6-positions of said heptapeptide moiety may each be optionally .alpha.

Abstract: The invention provides polypeptides of formula I,A--B--Gly--D--E IwhereinA is Tyr or substituted Tyr,B is --Gly-- or --(D)Ala--,D is, for example, Phe or MePheand E is, for example, --Met--X, --Leu--X,--Nle--X, --Nva--X, --Ile--X, methioninesulphoxide--X, methioninesulphone--X wherein X is --NR'R" or --OR'" and each of R', R" and R'" independently signifies hydrogen or alkyl of 1 to 5 carbon atoms,which compounds possess pharmacological activity, for example, analgesic activity.

Abstract: N-Acyl-polypeptides comprising the basic sequence ##STR1## wherein "Acyl" is the acyl residue of an organic or inorganic acid; A is H or alkyl; >N--CH(Z)--CO-- and E are the residues of natural .alpha.-amino acids or corresponding (D)-amino acids; C is --Trp-- or --(D)Trp--; F is a terminal grouping; and Y.sub.1 and Y.sub.2 are each H or together are a direct bond; as well as their salt forms and complexes.

Abstract: Pentapeptides of formula I, ##STR1## wherein Z.sup.1 =H, CH.sub.3 or amidino; R.sub.1 =H or alkyl and R.sub.2 =H or R.sub.1 +R.sub.2 =--CH.sub.2 --CH.sub.2 --; R.sub.3 =m- or p--OH or -alkoxy; B=residue of a (D)-.alpha.-amino acid; R.sub.4 =H or alkyl; Z.sup.2 =optionally substituted phenyl; and E=.beta.-amino alcohol residue (whereby when Z.sup.1 =H or CH.sub.3, R.sub.4 =C.sub.3-4 -alkyl) as well as their esters and the acid addition salts and complexes of such peptides and esters. Compounds according to the invention have valuable pharmacological, in particular LH-secretion inhibiting activity.

Abstract: Straight-chain and mono-cyclic polypeptides containing the basic sequence ##STR1## wherein X is an amino acid residue, the residues in the 1- and 6-positions being linked by an --S--S-- bridge when the polypeptide is monocyclic, have pharmacological, in particular GH--, gastric- and pancreatic-secretion inhibiting activity.

Abstract: The invention provides polypeptides of formula I,A-B-Gly-D-E Iwherein A is Tyr or substituted Tyr,B is -Gly- or -(D)Ala-,D is, for example, Phe or MePhe andE is, for example, -Met-X, -Leu-X, -Nle-X, -Nva-X, -Ile-X, methioninesulhoxide-X, methioninesulphone-X wherein X is --NR'R" or --OR'" and each of R', R" and R'" independently signifies hydrogen or alkyl of 1 to 5 carbon atoms,which compounds possess pharmacological activity, for example, analgesic activity.

Abstract: The invention provides polypeptides of the formula,A-B-Gly-D-E-FwhereinA is Tyr or substituted Tyr,B is, for example, -Gly-, -(D)-Ala-, or -(D)-Met-,D is Phe or substituted Phe,E is, for example, -Leu-, -Nle-, -Nva-, -Ile- or -Val-,and F is -NR.sub.7 CHR.sub.8 CH.sub.2 OR.sub.3 ',wherein, for example, R.sub.3 ' may be hydrogen or alkyl--CO--, R.sub.7 is hydrogen or alkyl and R.sub.8 is alkyl,which compounds possess pharmacological activity, for example, analgesic activity.

Abstract: The invention provides polypeptides useful, for example, as soporifics, a process for the preparation thereof and compositions containing these compounds.

Abstract: This invention provides new compounds of formula I, ##STR1## wherein X is H-Ala, D-Ala, .beta.-Ala, propionyl or Ac-Ala (wherein Ac is pharmaceutically acceptable acyl),Y is hydrogen or a direct bond between the sulphur atoms in positions 3 and 14, andZ is the radical --COOH, --COOR.sub.1 (wherein R.sub.1 is lower alkyl), ##STR2## (wherein R.sub.2 and R.sub.3 independently are hydrogen or lower alkyl) or --CH.sub.2 OH,with the proviso that X is other than H-Ala, when Z is COOH.useful as agents for the treatment of Diabetes Mellitus, acromegaly and angiopathy.

Abstract: This invention provides new compounds of formula I, ##SPC1##wherein R.sub.1 and R.sub.2 are hydrogen or lower alkyl, useful as anti-hypertensive agents.